MCID: LSH001
MIFTS: 69

Leishmaniasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Leishmaniasis

MalaCards integrated aliases for Leishmaniasis:

Name: Leishmaniasis 12 77 54 56 44 3 45 15 17 74
Post-Kala-Azar Dermal Leishmaniasis 12 74
Post-Kala-Azar Dermal Infectious Disease by Leishmaniasis 12
Post Kala-Azar Dermal Leishmaniasis 12
Leishmaniasis, Cutaneous 74
Cutaneous Leishmaniasis 54
Leishmaniasis, Visceral 74
Visceral Leishmaniasis 54
Kala-Azar 54

Classifications:



Summaries for Leishmaniasis

MedlinePlus : 44 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver, and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Leishmaniasis is found in parts of about 88 countries. Most of these countries are in the tropics and subtropics. It is possible but very unlikely that you would get this disease in the United States. But you should be aware of it if you are traveling to the Middle East or parts of Central America, South America, Asia, Africa or southern Europe. Treatment is with medicines that contain antimony, a type of metal, or with strong antibiotics. The best way to prevent the disease is to protect yourself from sand fly bites: Stay indoors from dusk to dawn, when sand flies are the most active Wear long pants and long-sleeved shirts when outside Use insect repellent and bed nets as needed Centers for Disease Control and Prevention

MalaCards based summary : Leishmaniasis, also known as post-kala-azar dermal leishmaniasis, is related to visceral leishmaniasis and cutaneous leishmaniasis, and has symptoms including fever, pruritus and exanthema. An important gene associated with Leishmaniasis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Miconazole and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and t cells, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus Leishmania, which is transmitted by the bite of sand fly (subfamily Phlebotominae).

NIH Rare Diseases : 54 Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Visceral disease can be deadly without proper treatment. Leishmaniasis is found in parts of the Middle East, Central America, South American, Asia, Africa, and southern Europe. Most of these countries are in the tropics and subtropics. It is possible but very unlikely to get this disease in the United States.

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

Wikipedia : 77 Leishmaniasis is a disease caused by parasites of the Leishmania type. It is spread by the bite of... more...

Related Diseases for Leishmaniasis

Diseases related to Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 502)
# Related Disease Score Top Affiliating Genes
1 visceral leishmaniasis 34.7 IFNG IL10 IL4 NOS2 SLC11A1 TLR2
2 cutaneous leishmaniasis 34.3 IFNG IL10 IL4 IL5 MPI SLC11A1
3 human immunodeficiency virus infectious disease 31.4 IFNG IL10 TNF
4 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.3 IFNG IL10 IL4
5 trypanosomiasis 31.3 IFNG IL10 IL1B IL4 TLR2 TNF
6 chagas disease 31.2 IFNG IL10 IL1B NOS2 TLR2 TLR4
7 leprosy 3 31.1 IFNG IL10 SLC11A1 TLR2 TNF
8 arthritis 31.0 HLA-DRB1 IFNG IL10 IL1A IL1B TNF
9 conjunctivitis 31.0 IFNG IL4 IL5
10 acquired immunodeficiency syndrome 30.7 IFNG IL10 IL1B RN7SL1 TNF
11 lepromatous leprosy 30.7 IFNG IFNGR1 IL10 TLR2 TNF
12 pericarditis 30.6 IFNG IL1B TNF
13 pulmonary tuberculosis 30.6 HLA-DRB1 IFNG IFNGR1 IL10 IL4 SLC11A1
14 filariasis 30.6 IFNG IL10 IL5 TLR2 TLR4 TNF
15 rheumatoid arthritis 30.5 HLA-DRB1 IFNG IL10 IL1A IL1B IL4
16 toxoplasmosis 30.5 IFNG IL10 IL1B IL4 TLR2 TLR4
17 meningitis 30.5 IFNG IL10 IL1B TLR2 TNF
18 uveitis 30.5 IFNG IL10 IL1A IL4 TNF
19 schistosomiasis 30.4 IFNG IFNGR1 IL10 IL4 IL5 TNF
20 malaria 30.4 HLA-DRB1 IFNG IFNGR1 IL10 IL1A IL1B
21 systemic lupus erythematosus 30.4 FCGR1A HLA-DRB1 IFNG IL10 IL1B IL4
22 sezary's disease 30.4 IFNG IL4 IL5
23 hepatitis a 30.4 IFNG IL10 TNF
24 melioidosis 30.4 IFNG IL10 TLR2 TLR4 TNF
25 endocarditis 30.4 IL10 TLR2 TNF
26 filarial elephantiasis 30.4 IL10 IL4 IL5 TLR2
27 panuveitis 30.4 HLA-DRB1 IL10 TNF
28 prostatitis 30.3 IL10 IL1B TNF
29 keratitis, hereditary 30.3 IL1B TLR2 TLR4
30 rheumatic disease 30.3 HLA-DRB1 IFNG IL10 IL1B TNF
31 bacterial infectious disease 30.3 FCGR1A IFNG IL10 IL1B ITGAM SLC11A1
32 connective tissue disease 30.3 HLA-DRB1 IFNG IL10 IL1A TNF
33 orofacial granulomatosis 30.2 IFNG IL10 IL4 TNF
34 coccidiosis 30.2 IFNG IL10 IL4 TNF
35 mixed connective tissue disease 30.2 HLA-DRB1 IFNG IL10 TNF
36 bacterial sepsis 30.2 IL10 NOS2 TLR4 TNF
37 multiple sclerosis 30.1 HLA-DRB1 IFNG IL10 IL1B IL4 NOS2
38 leptospirosis 30.1 IFNG IL10 IL1B TLR2 TNF
39 aphthous stomatitis 30.1 IL10 IL1B IL4 TLR2 TNF
40 psoriatic arthritis 30.1 HLA-DRB1 IL1A IL1B TNF
41 fascioliasis 30.1 IFNG IL10 IL1B
42 brucellosis 30.1 IFNG IL10 IL4 SLC11A1 TLR4 TNF
43 tonsillitis 30.1 IFNG IL1A IL1B IL4 TNF
44 pneumonia 30.0 IL10 IL1B IL5 TLR2 TLR4 TNF
45 onchocerciasis 30.0 IL4 IL5 MPI
46 autoimmune disease 30.0 HLA-DRB1 IFNG IL10 IL1B IL4 TNF
47 paracoccidioidomycosis 30.0 IFNG IL10 IL4 IL5 TLR2 TLR4
48 hematopoietic stem cell transplantation 30.0 IFNG IL10 TNF
49 typhoid fever 30.0 IFNG IFNGR1 IL1B SLC11A1 TLR4 TNF
50 graft-versus-host disease 30.0 HLA-DRB1 IFNG IL10 IL1A IL1B TNF

Graphical network of the top 20 diseases related to Leishmaniasis:



Diseases related to Leishmaniasis

Symptoms & Phenotypes for Leishmaniasis

Human phenotypes related to Leishmaniasis:

33 (show all 24)
# Description HPO Frequency HPO Source Accession
1 splenomegaly 33 hallmark (90%) HP:0001744
2 hepatomegaly 33 hallmark (90%) HP:0002240
3 pancytopenia 33 hallmark (90%) HP:0001876
4 abnormal bleeding 33 hallmark (90%) HP:0001892
5 skin ulcer 33 hallmark (90%) HP:0200042
6 papule 33 hallmark (90%) HP:0200034
7 lymphadenopathy 33 hallmark (90%) HP:0002716
8 skin plaque 33 hallmark (90%) HP:0200035
9 rhinitis 33 hallmark (90%) HP:0012384
10 night sweats 33 hallmark (90%) HP:0030166
11 recurrent fever 33 hallmark (90%) HP:0001954
12 abnormal oral mucosa morphology 33 hallmark (90%) HP:0011830
13 abnormal macrophage morphology 33 hallmark (90%) HP:0004311
14 arthralgia 33 frequent (33%) HP:0002829
15 anemia 33 frequent (33%) HP:0001903
16 pallor 33 frequent (33%) HP:0000980
17 weight loss 33 frequent (33%) HP:0001824
18 elevated hepatic transaminase 33 frequent (33%) HP:0002910
19 increased antibody level in blood 33 frequent (33%) HP:0010702
20 hypoalbuminemia 33 frequent (33%) HP:0003073
21 fatigue 33 occasional (7.5%) HP:0012378
22 thrombocytopenia 33 occasional (7.5%) HP:0001873
23 anorexia 33 occasional (7.5%) HP:0002039
24 leukopenia 33 occasional (7.5%) HP:0001882

UMLS symptoms related to Leishmaniasis:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Leishmaniasis:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 FCGR1A IFNG IFNGR1 IL10 IL1A IL1B
2 immune system MP:0005387 10.25 FCGR1A IFNG IFNGR1 IL10 IL1A IL1B
3 cellular MP:0005384 10.24 FCGR1A IFNG IFNGR1 IL10 IL4 ITGAM
4 cardiovascular system MP:0005385 10.21 IFNG IFNGR1 IL10 IL1A IL1B MPI
5 homeostasis/metabolism MP:0005376 10.21 IFNG IFNGR1 IL10 IL1A IL1B IL4
6 digestive/alimentary MP:0005381 10.18 IFNG IFNGR1 IL10 IL4 IL5 NOS2
7 integument MP:0010771 10.07 IFNG IFNGR1 IL10 IL1A IL1B IL4
8 neoplasm MP:0002006 10 IFNG IFNGR1 IL10 IL1A IL1B IL5
9 liver/biliary system MP:0005370 9.97 IFNG IFNGR1 IL10 IL4 IL5 NOS2
10 nervous system MP:0003631 9.9 IFNG IFNGR1 IL10 IL1B IL4 ITGAM
11 respiratory system MP:0005388 9.56 IFNG IL10 IL4 IL5 NOS2 TLR2
12 skeleton MP:0005390 9.36 FCGR1A IFNG IFNGR1 IL10 IL1B IL4

Drugs & Therapeutics for Leishmaniasis

Drugs for Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 5280965 14956
3
Miltefosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
4
deoxycholic acid Approved Phase 4,Phase 3,Not Applicable 83-44-3 222528
5
Paromomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 7542-37-2, 1263-89-4 165580
6
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3 137-58-6 3676
7
Primaquine Approved Phase 4 90-34-6 4908
8
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
9
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
10
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
11
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
12
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3 147127-20-6 464205
13
meglumine antimoniate Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 133-51-7
14 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
23 Analgesics Phase 4,Phase 2,Phase 3
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
25 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3
26 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Not Applicable
27 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
28 Antiviral Agents Phase 4,Phase 3,Not Applicable
29 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3,Not Applicable
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Not Applicable
31 Cholagogues and Choleretics Phase 4,Phase 3,Not Applicable
32 Anesthetics Phase 4
33 Chloroquine diphosphate Phase 4 50-63-5
34 Antimalarials Phase 4
35
protease inhibitors Phase 4,Phase 3
36 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
37 HIV Protease Inhibitors Phase 4,Phase 3
38 Atazanavir Sulfate Phase 4
39 Reverse Transcriptase Inhibitors Phase 4,Phase 3
40 Anti-HIV Agents Phase 4,Phase 3
41 Anti-Retroviral Agents Phase 4,Phase 3
42 Cytochrome P-450 CYP3A Inhibitors Phase 4
43 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4,Phase 3
44 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3
45 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3
46
Ethanol Approved Phase 2, Phase 3 64-17-5 702
47
Petrolatum Approved, Investigational Phase 2, Phase 3 8009-03-8
48
Salicylic acid Approved, Investigational, Vet_approved Phase 2, Phase 3 69-72-7 338
49
Pentoxifylline Approved, Investigational Phase 2, Phase 3,Phase 3 6493-05-6 4740
50
carbamide peroxide Approved Phase 3,Phase 2 124-43-6

Interventional clinical trials:

(show top 50) (show all 160)
# Name Status NCT ID Phase Drugs
1 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Unknown status NCT01566552 Phase 4 AMBISOME
2 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
3 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
4 Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis Completed NCT00317980 Phase 4 Meglumine antimoniate;Meglumine antimoniate
5 Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients Completed NCT00818818 Phase 4 Meglumine antimoniate
6 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
7 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4 Sodium stibogluconate
8 Pharmacokinetics of Miltefosine in Children and Adults Completed NCT01462500 Phase 4 Miltefosine
9 Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh Completed NCT03311607 Phase 4 AmBisome
10 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
11 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
12 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
13 Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia Unknown status NCT00487253 Phase 3 Miltefosine;Meglumine antimoniate
14 Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Unknown status NCT02151630 Phase 2, Phase 3 Pyruvic acid;Salicylic Acid
15 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Completed NCT01301924 Phase 2, Phase 3 Meglumine antimoniate
16 Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01381055 Phase 2, Phase 3 Pentoxifylline;Placebo
17 Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis Completed NCT01464242 Phase 2, Phase 3 Meglumine antimonate;Placebo;Pentoxifylline
18 Liposomal Amphotericin in Disseminated Leishmaniasis Completed NCT02025491 Phase 3 Liposomal Amphotericin B
19 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
20 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
21 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
22 Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia) Completed NCT00606580 Phase 3 WR 279,396 topical cream;Paromomycin Alone topical cream;Vehicle placebo cream
23 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3 Pentamidine
24 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
25 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
26 Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia. Completed NCT00471705 Phase 3 Miltefosine;Glucantime®
27 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
28 Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis Completed NCT00257530 Phase 3 Imiquimod
29 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
30 Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama Completed NCT01790659 Phase 3 WR 279,396;Paromomycin
31 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
32 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
33 Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul Completed NCT00947362 Phase 2, Phase 3 DAC N-055;saline
34 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
35 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
36 Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia Completed NCT03096457 Phase 2, Phase 3 Paromomycin Sulfate;Pentamidine Isethionate
37 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
38 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
39 Clinical Trial for the Treatment of Diabetic Foot Ulcers Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
40 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
41 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
42 Nicotinamide in the Treatment of Psoriasis Completed NCT01763424 Phase 2, Phase 3 Calcipotriol plus Nicotinamide;Calcipotriol
43 Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Completed NCT01348308 Phase 3 Maraviroc (Celsentri);Placebo
44 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3 Meglumine antimoniate
45 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
46 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3 Miltefosine
47 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Active, not recruiting NCT01435018 Phase 3 Etoposide (ET);Bleomycin and Vincristine (BV);Paclitaxel (PTX);Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
48 Miltefosine and GM-CSF in Cutaneous Leishmaniasis Not yet recruiting NCT03023111 Phase 3 Sbv;Miltefosine plus placebo;Miltefosine plus GM-CSF
49 Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Not yet recruiting NCT03829917 Phase 2, Phase 3 Miltefosine and Paromomycin;miltefosine;paromomycin
50 High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus Terminated NCT01953744 Phase 3 Fluconazole;Meglumine Antimoniate

Search NIH Clinical Center for Leishmaniasis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: leishmaniasis

Genetic Tests for Leishmaniasis

Anatomical Context for Leishmaniasis

MalaCards organs/tissues related to Leishmaniasis:

42
Testes, Skin, T Cells, Liver, Bone, Spleen, Bone Marrow

Publications for Leishmaniasis

Articles related to Leishmaniasis:

(show top 50) (show all 7546)
# Title Authors Year
1
Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia, Acanthamoeba, Balamuthia, and Naegleria in solid organ transplant recipients- Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. ( 30900295 )
2019
2
Leishmaniasis and Chagas Disease - Neglected Tropical Diseases: Treatment Updates. ( 30950334 )
2019
3
N-Nitrosulfonamides as Carbonic Anhydrase Inhibitors: A Promising Chemotype for Targeting Chagas Disease and Leishmaniasis. ( 30996772 )
2019
4
Anti-tumour necrosis factor-associated cutaneous leishmaniasis: a single-institution experience. ( 30659588 )
2019
5
Resolution of Cutaneous Leishmaniasis and Persistence of Leishmania major in the Absence of Arginase 1. ( 30665936 )
2019
6
How cutaneous leishmaniasis and treatment impacts in the patients' lives: A cross-sectional study. ( 30682151 )
2019
7
The increase in neglected cutaneous leishmaniasis in Gaziantep province of Turkey after mass human migration. ( 30710533 )
2019
8
Cutaneous Leishmaniasis: Updates in Diagnosis and Management. ( 30712756 )
2019
9
Isolated conjunctival involvement in a case of cutaneous leishmaniasis. ( 30722746 )
2019
10
Detection, genotyping, and phylogenetic analysis of Leishmania isolates collected from infected Jordanian residents and Syrian refugees who suffered from cutaneous leishmaniasis. ( 30729301 )
2019
11
Intralesional sodium stibogluconate under inhaled anesthesia for the treatment of cutaneous leishmaniasis in children: A retrospective cohort. ( 30731176 )
2019
12
Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis. ( 30738195 )
2019
13
Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways. ( 30771740 )
2019
14
Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B. ( 30774067 )
2019
15
Chitosan-based biocompatible dressing for treatment of recalcitrant lesions of cutaneous leishmaniasis: A pilot clinical study. ( 30785121 )
2019
16
Leishmania spp. Infection Rate and Feeding Patterns of Sand Flies (Diptera: Psychodidae) from a Hyperendemic Cutaneous Leishmaniasis Community in Panamá. ( 30793681 )
2019
17
Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates. ( 30802261 )
2019
18
Thirty years of cutaneous leishmaniasis in Tadla-Azilal focus, Morocco. ( 30805563 )
2019
19
Histological and immunological differences between zoonotic cutaneous leishmaniasis due to Leishmania major and sporadic cutaneous leishmaniasis due to Leishmania infantum. ( 30810524 )
2019
20
Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis. ( 30815688 )
2019
21
Diel periodicity and visual cues guide oviposition behavior in Phlebotomus papatasi, vector of old-world cutaneous leishmaniasis. ( 30835733 )
2019
22
Disseminated Cutaneous Leishmaniasis in a Patient Infected by Leishmania panamensis. ( 30843505 )
2019
23
Host and parasite responses in human diffuse cutaneous leishmaniasis caused by L. amazonensis. ( 30845223 )
2019
24
Imported cutaneous leishmaniasis: a 13-year experience of a Polish tertiary center. ( 30858788 )
2019
25
Alterations in monocyte subsets and cytokine production after TLR activation in American Cutaneous Leishmaniasis. ( 30870579 )
2019
26
Performance of immunohistochemistry as a useful tool for the diagnosis of cutaneous leishmaniasis in Panama, Central America. ( 30885795 )
2019
27
10-Year Trends in Epidemiology, Diagnosis, and Treatment of Cutaneous Leishmaniasis in Hamadan Province, West of Iran (2007-2016). ( 30891438 )
2019
28
The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice. ( 30898544 )
2019
29
Expansion of urban cutaneous leishmaniasis into rural areas of southeastern Iran: Clinical, epidemiological and phylogenetic profiles explored using 7SL high resolution melting-PCR analysis. ( 30912874 )
2019
30
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. ( 30922847 )
2019
31
Cutaneous Leishmaniasis caused by L. Infantum. ( 30925973 )
2019
32
The epidemiology of cutaneous leishmaniasis in Golestan Province, Iran: A cross-sectional study of 8-years. ( 30937404 )
2019
33
A Case of Cutaneous Leishmaniasis Caused by Leishmania infantum ( 30938136 )
2019
34
Prevalence of Cutaneous Leishmaniasis in Western Highlands in Yemen. ( 30941183 )
2019
35
Binational burden of American cutaneous leishmaniasis in Oiapoque, Amapá State, Brazil, bordering French Guiana. ( 30942256 )
2019
36
The therapeutic effect of ozonated olive oil plus glucantime on human cutaneous leishmaniasis. ( 30944704 )
2019
37
Study of the efficacy of N-methyl glucamine antimoniate (SbV) associated with photodynamic therapy using liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL6 mice. ( 30951865 )
2019
38
Prevalence of Leishmania species among patients with cutaneous leishmaniasis in Qassim province of Saudi Arabia. ( 30953481 )
2019
39
Level of circulating steroid hormones in malaria and cutaneous leishmaniasis: a case control study. ( 30956446 )
2019
40
Epidemiological features of a recent zoonotic cutaneous leishmaniasis outbreak in Zagora province, southern Morocco. ( 30964864 )
2019
41
Cutaneous leishmaniasis: an evolving disease with ancient roots. ( 30968403 )
2019
42
Cutaneous leishmaniasis among Syrian refugees in Jordan. ( 30974096 )
2019
43
Identification of priority areas for surveillance of cutaneous leishmaniasis using spatial analysis approaches in Southeastern Brazil. ( 30975100 )
2019
44
Experimental Cutaneous Leishmaniasis: Mouse Models for Resolution of Inflammation Versus Chronicity of Disease. ( 30980313 )
2019
45
Chronic Relapsing Cutaneous Leishmaniasis in an Elderly Female: A Rare Clinical Presentation from a Nonendemic Area. ( 30984593 )
2019
46
An outbreak of cutaneous leishmaniasis among a displaced population in North Sudan: Review of cases. ( 30984672 )
2019
47
The topical treatment of old world cutaneous leishmaniasis with gentian violet along with cryotherapy: a pilot single-blind randomized controlled clinical trial. ( 30994790 )
2019
48
First report of treatment failure in a patient with cutaneous leishmaniasis infected by Leishmania (Viannia) naiffi carrying Leishmania RNA virus: a fortuitous combination? ( 30994803 )
2019
49
Activated cytotoxic T cells within zoonotic cutaneous leishmaniasis lesions. ( 30997749 )
2019
50
Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis. ( 30999735 )
2019

Variations for Leishmaniasis

Expression for Leishmaniasis

Search GEO for disease gene expression data for Leishmaniasis.

Pathways for Leishmaniasis

Pathways related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 FCGR1A HLA-DRB1 IFNG IFNGR1 IL10 IL1A
2
Show member pathways
13.76 IFNG IFNGR1 IL10 IL1A IL1B IL4
3
Show member pathways
13.62 IFNG IFNGR1 IL10 IL1A IL1B IL4
4
Show member pathways
13.52 IL10 IL1A IL1B IL4 IL5 ITGAM
5
Show member pathways
13.46 FCGR1A HLA-DRB1 IFNG IFNGR1 IL10 IL1A
6
Show member pathways
13.34 HLA-DRB1 IFNG IFNGR1 IL1A IL1B IL4
7
Show member pathways
13.23 IFNG IFNGR1 IL10 IL1B NOS2 TLR2
8
Show member pathways
13 HLA-DRB1 IFNG IFNGR1 IL10 IL1A IL1B
9 12.88 IFNG IFNGR1 IL4 IL5 NOS2
10
Show member pathways
12.76 IL1A IL1B TLR2 TLR4 TNF
11
Show member pathways
12.75 HLA-DRB1 IFNG IFNGR1 IL10 IL4 TNF
12
Show member pathways
12.74 IFNG IFNGR1 IL1A IL1B TNF
13
Show member pathways
12.71 IFNG IL10 IL1A IL1B IL4 IL5
14 12.7 IFNG IL10 IL1B IL4 TLR2 TNF
15
Show member pathways
12.68 IL1A IL1B TLR2 TLR4 TNF
16
Show member pathways
12.66 IFNG IL10 IL1B NOS2 TNF
17
Show member pathways
12.53 HLA-DRB1 IFNG IFNGR1 IL10 IL1A IL1B
18
Show member pathways
12.49 IFNG IFNGR1 IL10 IL4 IL5
19
Show member pathways
12.49 IFNG IL1B IL4 IL5 TLR2 TNF
20
Show member pathways
12.47 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
21
Show member pathways
12.42 IFNG IL10 IL1A IL1B IL4 IL5
22
Show member pathways
12.39 IFNG IL1B IL4 TNF
23
Show member pathways
12.37 IFNG IFNGR1 IL1A IL1B TLR4 TNF
24
Show member pathways
12.36 IL1A IL1B NOS2 TLR2 TNF
25 12.34 IFNG IFNGR1 NOS2 TLR2 TLR4 TNF
26
Show member pathways
12.32 IL1A TLR2 TLR4 TNF
27
Show member pathways
12.31 IFNG IFNGR1 IL1B IL4 NOS2 TLR2
28 12.28 FCGR1A HLA-DRB1 ITGAM TLR2 TLR4
29 12.25 IL10 IL1A IL1B TNF
30
Show member pathways
12.24 FCGR1A HLA-DRB1 IFNG IFNGR1 IL10 IL1A
31
Show member pathways
12.23 IFNG IFNGR1 IL10 IL1A IL1B IL4
32
Show member pathways
12.22 IFNG IFNGR1 IL10 IL1B TLR2 TLR4
33 12.21 FCGR1A IFNG IFNGR1 IL1A IL1B TNF
34 12.18 IFNG IL1A IL1B TNF
35
Show member pathways
12.18 IL1A IL1B IL5 TLR2 TLR4
36 12.17 IFNG IL1A IL1B IL4 NOS2 TLR4
37 12.15 IFNG IL10 IL4 IL5 ITGAM TNF
38
Show member pathways
12.14 HLA-DRB1 IFNG IL1B IL4 NOS2
39 12.14 IL10 IL1A IL1B IL4 ITGAM NOS2
40
Show member pathways
12.14 FCGR1A IFNG IL1B IL4 ITGAM TLR2
41 12.02 IFNG IFNGR1 NOS2 TLR4
42 12.01 HLA-DRB1 IFNG IL1A IL1B TLR2 TLR4
43 12 IFNG IFNGR1 IL1A IL1B NOS2 TLR4
44 11.99 FCGR1A HLA-DRB1 IFNG IFNGR1 IL10 IL1A
45 11.96 FCGR1A HLA-DRB1 IL1A IL1B IL4 IL5
46 11.95 FCGR1A ITGAM TLR2 TLR4
47 11.93 IL1B TLR4 TNF
48 11.92 IFNG IL10 IL1B ITGAM TNF
49 11.92 IFNG IL10 IL1B IL4 IL5 ITGAM
50 11.91 IFNG IL10 IL1B ITGAM NOS2 TLR2

GO Terms for Leishmaniasis

Cellular components related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 IFNG IL10 IL1A IL1B IL4 IL5

Biological processes related to Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 IL1B TLR2 TLR4 TNF
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.95 IL10 IL1B IL5 TNF
3 cellular response to lipopolysaccharide GO:0071222 9.95 IL10 IL1B NOS2 TLR4 TNF
4 defense response to Gram-negative bacterium GO:0050829 9.9 NOS2 SLC11A1 TLR4
5 positive regulation of JNK cascade GO:0046330 9.89 IL1B TLR4 TNF
6 positive regulation of inflammatory response GO:0050729 9.89 TLR2 TLR4 TNF
7 interferon-gamma-mediated signaling pathway GO:0060333 9.88 FCGR1A HLA-DRB1 IFNG IFNGR1
8 regulation of insulin secretion GO:0050796 9.87 IFNG IL1B NOS2 TNF
9 positive regulation of gene expression GO:0010628 9.86 IFNG IL1A IL1B IL4 SLC11A1 TLR2
10 response to lipopolysaccharide GO:0032496 9.85 IL10 IL1B NOS2 SLC11A1 TLR2 TLR4
11 positive regulation of B cell proliferation GO:0030890 9.84 IL4 IL5 TLR4
12 positive regulation of phagocytosis GO:0050766 9.84 IL1B SLC11A1 TNF
13 positive regulation of interleukin-6 production GO:0032755 9.84 IL1B TLR2 TLR4 TNF
14 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.83 IL1A IL1B TNF
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 IL1B TLR2 TLR4 TNF
16 negative regulation of interferon-gamma production GO:0032689 9.82 HLA-DRB1 IL10 TLR4
17 negative regulation of interleukin-6 production GO:0032715 9.81 IL10 TLR4 TNF
18 positive regulation of cytokine secretion GO:0050715 9.81 IL10 IL1A TNF
19 positive regulation of interferon-gamma production GO:0032729 9.81 IL1B SLC11A1 TLR4 TNF
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 IFNG IL1B TLR4 TNF
21 positive regulation of interleukin-12 production GO:0032735 9.78 IFNG TLR2 TLR4
22 positive regulation of chemokine production GO:0032722 9.77 TLR2 TLR4 TNF
23 microglial cell activation GO:0001774 9.77 ITGAM TLR2 TNF
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.76 IFNG IL1B TNF
25 inflammatory response GO:0006954 9.76 IL10 IL1A IL1B IL5 SLC11A1 TLR2
26 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.73 TLR2 TLR4
27 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.73 IL1A IL1B
28 regulation of cytokine secretion GO:0050707 9.73 TLR2 TLR4
29 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.73 IFNG IFNGR1
30 I-kappaB phosphorylation GO:0007252 9.73 TLR2 TLR4
31 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 IL10 IL1B TNF
32 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 IL1B TLR2 TLR4 TNF
33 negative regulation of interleukin-17 production GO:0032700 9.72 IFNG TLR4
34 positive regulation of podosome assembly GO:0071803 9.72 IL5 TNF
35 response to molecule of bacterial origin GO:0002237 9.72 IL10 TLR2
36 macrophage activation GO:0042116 9.72 SLC11A1 TLR4
37 cellular response to lipoteichoic acid GO:0071223 9.71 TLR2 TLR4
38 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.71 TLR4 TNF
39 T-helper 1 type immune response GO:0042088 9.71 HLA-DRB1 TLR4
40 response to glucocorticoid GO:0051384 9.71 IL10 TNF
41 positive regulation of interleukin-8 production GO:0032757 9.71 IL1B TLR2 TLR4 TNF
42 endothelial cell apoptotic process GO:0072577 9.7 IL10 TNF
43 positive regulation of chemokine biosynthetic process GO:0045080 9.7 IL1B TNF
44 ectopic germ cell programmed cell death GO:0035234 9.7 IL1A IL1B
45 regulation of establishment of endothelial barrier GO:1903140 9.7 IL1B TNF
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.69 IL10 TNF
47 positive regulation of neuroinflammatory response GO:0150078 9.69 IL1B TNF
48 positive regulation of fever generation GO:0031622 9.69 IL1B TNF
49 positive regulation of killing of cells of other organism GO:0051712 9.68 IFNG NOS2
50 regulation of isotype switching GO:0045191 9.68 IL10 IL4

Molecular functions related to Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 IFNG IL10 IL1A IL1B IL4 IL5
2 interleukin-1 receptor binding GO:0005149 9.16 IL1A IL1B
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....